Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Catholic University, Campobasso, Campobasso, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Campobasso
Treatments:ChemotherapyHospital:Catholic University, Campobasso
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This phase III trial involved 153 women with recurrent or progressive ovarian cancer. The median age was 63 years old, ranging from 28 to 80.

Treatment: The women were treated with either gemcitabine or pegylated liposomal doxorubicin. Both of these are chemotherapy drugs.

Toxicity: Grade 3/4 neutropenia was reported in 16 patients treated with gemcitabine and 5 patients treated with doxorubicin. Grade 3 or 4 anemia, thrombocytopenia, fatigue, nausea, diarrhea, mucositis, and allergic reaction occurred in up to 6% of patients.

Results: The median overall survival was 12.9 months (56 weeks) in patients treated with pegylated liposomal doxorubicin, and 11.7 months (51 weeks) in those treated with gemcitabine.

Correspondence: Dr. Gabriella Ferrandina



Back